

Original Article

Role of lymphoid immune factors in COPD patients complicated with pulmonary infection

Yao Teng*, Zhen Ge*, Yu Chen, Chenen Li, Cunhai Zhang

Department of Intensive Care Unit, The 903rd Hospital of People's Liberation Army, Hangzhou 310013, Zhejiang, China. *Equal contributors and co-first authors.

Received February 10, 2020; Accepted March 18, 2020; Epub June 15, 2020; Published June 30, 2020

Abstract: Objective: The aim of this study was to explore the role of lymphoid immune factors and their relationship with BODE index in chronic obstructive pulmonary disease (COPD) patients complicated with pulmonary infection. Method: One hundred and ninety-four patients with COPD, who were treated in our hospital, were selected as the study subjects. Among them, 81 cases were complicated with pulmonary infection (group A) and 113 cases were without pulmonary infection (group B). Another 55 healthy subjects were selected as controls (group C). The levels of T lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺) in peripheral blood were detected by flow cytometry. The correlation between T lymphocyte subsets and BODE index was analyzed by Spearman's test. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic value of T lymphocyte subsets in patients with COPD complicated with pulmonary infection. Logistic regression analysis was used to analyze the risk factors for COPD complicated with pulmonary infection. Results: The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group A and group B subjects were significantly lower than in group C subjects ($P < 0.001$). The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the peripheral blood of group A subjects were significantly lower than those in group B subjects ($P < 0.05$). There were no significant difference in the peripheral blood CD8⁺ cell levels between groups A, B, and C ($P > 0.05$). The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood were negatively correlated with the BODE index ($P < 0.001$), while CD8⁺ cells levels were not associated with BODE index grading ($P > 0.05$). The sensitivity of peripheral blood CD3⁺ cell levels for the diagnosis of COPD was 72.57% and the specificity was 65.43%, with an optimal cut-off value of 59.05. The sensitivity of peripheral blood CD4⁺ cell levels for the diagnosis of COPD was 60.40% and the specificity was 77.78%, with an optimal cut-off value of 29.74. The sensitivity of peripheral blood CD4⁺/CD8⁺ cell levels for the diagnosis of COPD was 51.68% and the specificity was 81.73%, with an optimal cut-off value of 1.45. Smoking history, nutritional status, and CD4⁺/CD8⁺ cell levels were independent risk factors for COPD patients complicated with pulmonary infection ($P < 0.05$). Conclusion: T lymphocyte subsets in COPD patients complicated with pulmonary infection are unbalanced, and patients' immune function is low. CD4⁺/CD8⁺ cell imbalance is an independent risk factor for COPD complicated with pulmonary infection. CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cell levels are associated with the BODE index and T lymphocyte subsets may be predictors of disease assessment and prognosis for COPD patients complicated with pulmonary infection.

Keywords: BODE index, chronic obstructive pulmonary disease, lymphoid immune factors, pulmonary infection, T lymphocyte subsets

Introduction

Chronic obstructive pulmonary disease (COPD) is a common chronic lung disease, with airflow limitation and progressive development in middle-aged and elderly individuals [1]. In recent years, increasing clinical research on COPD has helped define its characteristics of high incidence and high disability [2]. Pulmonary function progressively degenerates in COPD patients, which leads to a continuous decline in

the ability for physical activity and the quality of life. In addition, COPD can cause a series of complications that pose a great threat to the patient's quality of life [3]. Pulmonary infection is one of the most common complications of COPD. It can accelerate the progress of the disease, aggravate the impaired pulmonary function and respiratory tract damage, and make the treatment and recovery of patients more difficult [4]. At present, the pathogenesis of COPD has not been elucidated, but the release

Lymphoid immune factors in COPD patients

of various inflammatory mediators and immune dysfunction play important roles in its occurrence and development [5, 6]. Studies have shown that long-term chronic inflammation can alter the immune function of COPD patients, which mainly manifests as changes in T lymphocyte subsets (CD3⁺, CD4⁺, and CD8⁺) [7]. The imbalance of cellular immune function is thought to be the cause of concurrent infection in middle-aged and elderly patients. The decline in immune function can reduce the number of T lymphocytes and cause an imbalance of their subpopulations [8]. Half of COPD patients suffer from malnutrition and malignant diseases. Severe malnutrition can affect the function of lymphocytes [9]. Studies have shown that COPD with pulmonary infection is associated with smoking and malnutrition [10]. Other studies have confirmed that factors such as interleukin-6, C-reactive protein, and procalcitonin are associated with pulmonary infection in patients with COPD [11, 12].

In recent years, there have been many studies on the control of COPD complicated with pulmonary infection [13, 14], but there has been little research on the role of T lymphocyte subsets in the occurrence and development of COPD.

To understand the mechanism of COPD complicated with pulmonary infection, this study examined CD3⁺, CD4⁺, and CD8⁺ T lymphocyte subsets in the peripheral blood of COPD patients. The role of the T lymphocyte subset ratio in the occurrence and development of COPD complicated with pulmonary infection and its relationship with the BODE index were investigated.

Methods

One hundred and ninety-four patients with COPD, who were treated in our hospital, were selected as the study subjects. This included 118 males and 76 females. The subjects were 45-79 years old, with an average age of 61.62±8.96 years. The length of their medical history was 10-39 years, with an average of 15.43±5.97 years. There were 81 cases with pulmonary infection (group A) and 113 cases without pulmonary infection (group B). Subjects were included in the study if their diagnosis and treatment occurred in accordance with COPD guidelines [15] and their pulmonary infections

were diagnosed by chest X-ray and bacteriological characteristics [16]. This study was approved by the ethics committee of our hospital and all subjects and their families provided signed, fully informed consent. Subjects were excluded if they had used antibiotics, anti-inflammatory drugs, or immunosuppressive drugs within the previous month; had other systemic autoimmune diseases, such as severe liver and kidney dysfunction, connective tissue diseases, or endocrine and metabolic diseases; had hematopoietic dysfunction, cardiac insufficiency, bronchiectasis, tuberculosis, rheumatic diseases, or other chronic inflammation; had other infections; or had psychiatric disorders or a family history of psychiatric disorders. An additional 55 healthy subjects were selected as the control group (group C). This group included 34 males and 21 females ranging in age from 40-61 years, with an average age of 56.62±7.16 years. No abnormalities were found upon physical examination, pulmonary ventilation function was normal, and there was no use of drugs that affect immune function in group C subjects.

Instruments and reagents

The anti-CD3-PE monoclonal antibody, anti-CD4-FITC monoclonal antibody, anti-CD8-APC monoclonal antibody were purchased from Becton Dickinson (Franklin Lakes, NJ, USA). A FACSCalibur automatic flow cytometer (Becton Dickinson) was used for flow cytometry experiments and centrifugation steps were performed using a Beckman Coulter centrifuge (Brea, CA, USA).

Sample collection and experimental procedures

On the morning after admission, 5 mL of peripheral blood was taken and placed into an EDTA anticoagulant tube. The number of T lymphocyte subsets and their ratios were determined using a FACSCalibur automatic flow cytometer. After centrifugation, the upper plasma layer was discarded and 2 mL of the supernatant suspension was added to a 10 mL centrifuge tube. After adding 8 mL of red blood cell lysate, samples were left at room temperature for 10 min and then centrifuged. The supernatant was then discarded and pellets were resuspended in 1 mL of PBS buffer. Red blood cell lysate were transferred to a 1.5 mL centrifuge tube

and after centrifugation, the upper liquid layer was discarded and 500 μ L of PBS buffer was added. Aliquots of 100 μ L each were then transferred to new 1.5 mL tubes. After staining, CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ levels were determined by flow cytometry.

Evaluation index

Evaluation and BODE index classification was performed according to the evaluation criteria reported by Celli et al. [17]. The evaluation included measurements of body mass index (BMI), the degree of airflow obstruction, dyspnea, and motor ability. BMI was defined as the ratio of weight/height (kg/m^2) and the degree of airflow obstruction was defined as the forced expiratory volume in 1 second as a percentage of the predicted value. Dyspnea was assessed by the Modified Dyspnea Index (mMRC) and exercise capacity was assessed by a 6-minute walking distance (6MWD) test. BMI was assessed by a two-level scoring method, with either 0 points or 1 point, while the other three parameters were assessed by a four-level scoring method, with 0-3 points. The maximum possible score was 10 points, with a higher score representing a more severe disease state. BODE scoring criteria were then determined as follows: 0-2 points, grade 1; 3-4 points, grade 2; 5-6 points, grade 3; and 7-10 points, grade 4. A higher BODE index grade represented a more severe disease state.

Statistical methods

SPSS 19.0 (IBM Corp, Armonk, NY, USA) was used for statistical analyses and graphs were prepared using Prism 7 (GraphPad, San Diego, CA, USA). Data are expressed as mean \pm standard deviation (SD). An independent samples t-test was used to compare data between groups. Counting data are expressed as both number and percentage [n (%)]. A Chi-square test was used to compare counting data between groups. Single-factor analysis of variance was used to compare means from multiple groups. Two-by-two comparisons were performed using a Dunnett's t-test. Correlations were analyzed by Spearman's test. Diagnostic value was determined using a receiver operating characteristic (ROC) curve. The factors affecting COPD combined with pulmonary infection were analyzed by logistic regression. $P < 0.05$ was considered statistically significant.

Results

General information for the three study groups

There were no significant differences in gender, age, or drinking history among groups A, B, and C ($P > 0.05$). COPD patients' course of disease, history of drinking, history of hypertension, history of heart failure, and history of mechanical ventilation were not associated with pulmonary infection ($P > 0.05$). However, pulmonary infection was associated with smoking history, diabetes history, respiratory failure history, hospitalization time, and nutritional status ($P < 0.05$, **Table 1**).

The levels of peripheral blood T lymphocyte subsets in the three groups

The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group A subjects were significantly lower than those in group C subjects ($t = 3.681$, $P < 0.001$; $t = 4.584$, $P < 0.001$; $t = 4.969$, $P < 0.001$; respectively). The levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group B subjects were also significantly lower than those in group C subjects ($t = 3.449$, $P < 0.001$; $t = 2.564$, $P = 0.011$; $t = 3.599$, $P < 0.001$; respectively). Furthermore, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group A subjects were significantly lower than those of group B subjects ($t = 2.221$, $P = 0.026$; $t = 3.061$, $P = 0.002$; $t = 1.981$, $P = 0.049$; respectively). However, there was no significant difference in peripheral blood CD8⁺ cell levels among groups A, B, group C ($P > 0.05$, **Table 2** and **Figure 1**).

The relationship between peripheral blood T lymphocyte subsets and BODE index classification

The BODE index for each patient was set to 1, 2, 3, or 4, as described in the "Materials and methods" section. The correlation between peripheral blood T lymphocyte subsets and BODE index grading was analyzed by Spearman's test. The results showed that peripheral blood CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cell levels were negatively correlated with BODE index ($r = -0.400$, $P < 0.001$; $r = -0.415$, $P < 0.001$; $r = -0.443$, $P < 0.001$; respectively). However, CD8⁺ cell levels were not associated with BODE index grading ($r = 0.114$, $P = 0.312$; **Figure 2**).

Lymphoid immune factors in COPD patients

Table 1. General information of study subjects [n (%)]

Category	n	Group A (n = 81)	Group B (n = 113)	Group C (n = 55)	χ^2 value	P value
Gender					1.259	0.533
Male	152	53 (65.43)	65 (57.52)	34 (61.82)		
Female	97	28 (34.57)	48 (42.48)	21 (38.18)		
Age)					1.961	0.375
≤ 60	34	8 (9.88)	16 (14.16)	10 (18.18)		
> 60	215	73 (90.12)	97 (85.84)	45 (81.82)		
Course of disease (year)					0.138	0.710
< 15	124	53 (65.43)	71 (62.83)	-		
≥ 15	70	28 (34.57)	42 (37.17)	-		
History of smoking					7.297	0.026
Yes	109	45 (55.56)	43 (38.05)	21 (36.36)		
No	140	36 (44.44)	70 (61.95)	34 (63.64)		
Drinking history					1.569	0.456
Yes	96	35 (43.21)	39 (34.51)	22 (40.00)		
No	153	46 (56.79)	74 (65.49)	33 (60.00)		
History of diabetes					6.845	0.009
Yes	63	30 (37.04)	33 (45.13)	-		
No	131	51 (62.96)	80 (54.87)	-		
History of hypertension					0.260	0.610
Yes	88	35 (43.21)	53 (46.90)	-		
No	106	46 (56.79)	60 (53.10)	-		
History of heart failure						
Yes	45	20 (24.69)	25 (22.12)	-		
No	149	61 (75.31)	88 (77.88)	-		
History of respiratory failure					6.832	0.009
Yes	28	18 (22.22)	10 (8.85)	-		
No	166	63 (77.78)	103 (91.15)	-		
History of mechanical ventilation					2.532	1.591
Yes	134	61 (75.31)	73 (64.60)	-		
No	60	20 (24.69)	40 (35.40)	-		
Hospital stay					4.906	0.027
≥ 12 d	150	69 (85.19)	81 (71.68)	-		
< 12 d	44	12 (14.81)	32 (28.32)	-		
Nutritional status					3.928	0.046
Albumin ≥ 25 g	137	51 (62.96)	86 (76.11)	-		
Albumin < 25 g	57	30 (37.04)	27 (23.89)	-		

Diagnostic value of peripheral blood T lymphocyte subset levels in patients with COPD complicated with pulmonary infection

ROC curves were constructed for the use of peripheral blood CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ cell levels in the diagnosis of COPD complicated with pulmonary infection. The area under the curve (AUC) for the diagnosis of COPD by CD3⁺ cell levels in the peripheral blood was 0.723 (95% CI: 0.650-0.796), with a diagnostic

sensitivity of 72.57%, a specificity of 65.43%, and an optimal cut-off value of 59.05. The AUC for the diagnosis of COPD by CD4⁺ cell levels in the peripheral blood was 0.687 (95% CI: 0.611-0.763), with a diagnostic sensitivity of 60.40%, a specificity of 77.78%, and an optimal cut-off value of 29.74. The AUC for the diagnosis of COPD by CD8⁺ cell levels in the peripheral blood was 0.638 (95% CI: 0.635-0.719), with a diagnostic sensitivity of 78.56%, a specificity of 53.41%, and an optimal cut-off value of 34.24.

Lymphoid immune factors in COPD patients

Table 2. Comparison of peripheral blood T lymphocyte subsets among the three groups (mean \pm SD)

T lymphocyte subset	Group A (n = 81)	Group B (n = 113)	Group C (n = 55)	F value	P value
CD3 ⁺ (%)	57.13 \pm 24.49 ^{*,#}	63.14 \pm 12.81 [*]	70.19 \pm 11.61	9.387	P < 0.001
CD4 ⁺ (%)	24.71 \pm 12.67 ^{*,#}	29.97 \pm 11.14 [*]	34.91 \pm 12.83	12.040	P < 0.001
CD8 ⁺ (%)	32.01 \pm 12.68	33.46 \pm 12.07	34.13 \pm 10.34	0.683	0.506
CD4 ⁺ /CD8 ⁺	1.02 \pm 0.78 ^{*,#}	1.24 \pm 0.75 [*]	1.68 \pm 0.73	12.620	P < 0.001

Note: ^{*}P < 0.05, compared with group C; [#]P < 0.05, compared with group B.




Figure 1. Comparison of peripheral blood T lymphocyte subsets among the three groups. Comparison of CD3⁺ (A), CD4⁺ (B), CD8⁺ (C), and CD4⁺/CD8⁺ (D) cell levels in the peripheral blood of the three study groups. Note: ^{*}P < 0.05, compared with group C; [#]P < 0.05, compared with group B.




Figure 2. Relationship between peripheral blood T lymphocyte subsets and BODE index grading. The relationship between CD3⁺ (A), CD4⁺ (B), CD8⁺ (C), and CD4⁺/CD8⁺ (D) cell levels in the peripheral blood of COPD patients and BODE index grading.

The AUC for the diagnosis of COPD by CD4⁺/CD8⁺ cell levels in the peripheral blood was 0.671 (95% CI: 0.594-0.749), with a diagnostic sensitivity of 51.68%, a specificity of 81.73%, and an optimal cut-off value of 1.45 (Table 3 and Figure 3).

Risk factors for COPD complicated with pulmonary infection

The optimal cut-off value of peripheral blood T lymphocyte subsets for the diagnosis of COPD complicated with pulmonary infection was used as the critical value. Logistic multivariate analysis showed that smoking history, nutritional status, and CD4⁺/CD8⁺ cell levels were independent risk factors for COPD complicated with pulmonary infection ($P < 0.05$). However, history of diabetes or respiratory failure; length of hospital stay; and CD3⁺, CD4⁺, or CD8⁺ cell levels had no association with pulmonary infection ($P > 0.05$; Tables 4, 5).

Discussion

COPD is a chronic respiratory disease with a high prevalence in humans. The high incidence and mortality in elderly and middle-aged individuals has resulted in a significant social and economic burden [18]. COPD can affect human lungs and cause systemic adverse

Lymphoid immune factors in COPD patients

Table 3. Diagnostic value of peripheral blood T lymphocyte subsets in patients with COPD complicated with pulmonary infection

Diagnostic indicator	AUC	95% CI	Standard error	Cut-off	Sensitivity (%)	Specificity (%)
CD3 ⁺	0.723	0.650-0.796	0.037	59.05	72.57	65.43
CD4 ⁺	0.687	0.611-0.763	0.039	29.74	60.40	77.78
CD8 ⁺	0.638	0.635-0.719	0.037	34.24	78.56	53.41
CD4 ⁺ /CD8 ⁺	0.671	0.594-0.749	0.039	1.45	51.68	81.73




Figure 3. ROC curves of peripheral blood CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ cell levels for the diagnosis of COPD with pulmonary infection. ROC curves of peripheral blood CD3⁺ (A), CD4⁺ (B) CD8⁺ (C), and CD4⁺/CD8⁺ (D) cell levels for the diagnosis of COPD complicated with pulmonary infection.

Table 4. Variable assignments of logistic regression analysis

Factor	Assignment
History of smoking	Yes = 1, No = 2
History of diabetes	Yes = 1, No = 2
History of respiratory failure	Yes = 1, No = 2
Hospital stay	≥ 12 d = 1, < 12 d = 2
Nutritional status	≥ 25 g = 1, < 25 g = 2
CD3 ⁺	≥ 59.05 = 1, < 59.05 = 2
CD4 ⁺	≥ 29.74 = 1, < 29.74 = 2
CD8 ⁺	≥ 34.24 = 1, < 34.24 = 2
CD4 ⁺ /CD8 ⁺	≥ 1.45 = 1, < 1.45 = 2

reactions, including malnutrition, weight loss, and skeletal muscle dysfunction. It can also cause pulmonary infection, with inflammation, glandular hypersecretion, and bronchial mucosal edema as the main clinical features. These complications have a serious impact on the patient's quality of life [19-21].

T lymphocyte subsets are the most important cell types of the immune system and each T lymphocyte subgroup interacts with each other to maintain normal immune system function [22]. The body maintains normal humoral and cellular immune functions through T lymphocyte subsets, complement C3 and C4, and immunoglobulin [23]. Previous studies have shown that abnormal levels of T lymphocytes and their subsets and an imbalance of immune function are important factors in the pathogenesis of COPD. Abnormal levels of apoptosis of CD3⁺, CD4⁺, and CD8⁺ cells in the peripheral blood of COPD patients can cause an imbalance of T lymphocyte subsets [24, 25]. Freeman et al. [26] showed that the number of CD8⁺ cells in the lung is related to the severity of COPD. The proinflammatory cytokines and cytotoxic molecules produced by CD8⁺ cells in the lung can cause damage to lung tissue. Wu et al. [27] found that immune dysfunction in patients with severe acute COPD is mainly manifested as a decrease in the number of CD3⁺ and CD4⁺ cells in the peripheral blood. Our results showed that the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group A and B subjects were significantly decreased compared with the levels in group C subjects. The decrease in CD3⁺ cell levels was due to a decrease in the total number of T lymphocytes, which was mainly caused by a decrease in the number of CD4⁺ cells. Freeman et al. [28] showed that peripheral blood CD4⁺ and CD8⁺ cells decreased during acute exacerbation of COPD and T cells could infiltrate into the sites of inflammation or lymphoid tissue. In our study, the decrease in the number of CD8⁺ cells was

Freeman et al. [26] showed that the number of CD8⁺ cells in the lung is related to the severity of COPD. The proinflammatory cytokines and cytotoxic molecules produced by CD8⁺ cells in the lung can cause damage to lung tissue. Wu et al. [27] found that immune dysfunction in patients with severe acute COPD is mainly manifested as a decrease in the number of CD3⁺ and CD4⁺ cells in the peripheral blood. Our results showed that the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ cells in the peripheral blood of group A and B subjects were significantly decreased compared with the levels in group C subjects. The decrease in CD3⁺ cell levels was due to a decrease in the total number of T lymphocytes, which was mainly caused by a decrease in the number of CD4⁺ cells. Freeman et al. [28] showed that peripheral blood CD4⁺ and CD8⁺ cells decreased during acute exacerbation of COPD and T cells could infiltrate into the sites of inflammation or lymphoid tissue. In our study, the decrease in the number of CD8⁺ cells was

Lymphoid immune factors in COPD patients

Table 5. Logistic multivariate analysis of risk factors for COPD complicated with pulmonary infection

Variable	β	SE	Wald	P value	OR value	95% CI
History of smoking	1.521	0.620	6.033	0.014	4.583	1.361-14.437
History of diabetes	0.199	0.623	0.131	0.724	1.224	0.362-4.128
History of respiratory failure	0.234	0.738	0.249	0.654	1.337	0.416-4.637
Hospital stay	0.700	0.179	15.313	0.069	2.014	1.418-2.861
Nutritional status	2.483	0.531	18.597	< 0.001	5.583	2.994-21.043
CD3 ⁺	0.518	0.586	0.773	0.376	1.686	0.531-5.294
CD4 ⁺	1.311	0.543	1.673	0.059	2.695	0.834-4.293
CD8 ⁺	0.183	0.634	0.080	0.724	1.194	0.343-4.176
CD4 ⁺ /CD8 ⁺	0.718	0.363	3.920	0.047	2.114	1.005-4.138

not significantly different among the three groups, which may be related to the redistribution of CD8⁺ cells. Pulmonary infection may be due to the combined effects of a decrease in the number of CD4⁺ cells and CD4⁺/CD8⁺ cells. Abnormal levels of CD3⁺ and CD4⁺/CD8⁺ cells can cause disorders of the immune system and a series of pathological changes, resulting in low overall immune function, impaired cellular immune function in COPD patients and anti-infective immunity in COPD patients.

The BODE index is considered an important index to evaluate the severity and prognosis of COPD patients. A higher score correlates with more severe disease and poorer prognosis [29]. Kumar et al. [30] showed that the BODE index can be used to assess the severity of illness, length of hospital stay, and mortality in patients with COPD. The variables included in the BODE index are simple to measure and can be easily and economically implemented. Therefore, the BODE index is a reliable evaluation method for classifying patients with COPD and making decisions on corresponding treatments to implement. There was been little research on the relationship between the BODE index and COPD immune index. Therefore, we investigated this relationship and found that levels of the peripheral blood T lymphocyte subsets, CD3⁺, CD4⁺, and CD4⁺/CD8⁺, were negatively correlated with the BODE index score. This suggests that the condition and prognosis of patients with COPD complicated with pulmonary infection may be related to an imbalance of T lymphocyte subsets. The risk factors for COPD complicated with pulmonary infection are a hot topic in clinical research. Exploring the risk factors of COPD combined with pulmonary infection is of great importance for pre-

venting infection, controlling the disease, relieving clinical symptoms, and improving the lung function of patients [31, 32]. There have been many studies on the risk factors for COPD complicated with pulmonary infection. For example, MCGOWN et al. [33] showed that cigarette smoke can affect important pathogens known to cause lung infections in COPD patients. Cigarette smoke extract enhances the pathogenicity of these bacteria, thereby worsening the prognosis of patients with COPD. Yang et al. [34] found that the long-term inhalation of glucocorticoids can increase the risk of upper respiratory tract infection in COPD patients. We performed a logistic regression analysis of the risk factors for pulmonary infection in COPD patients. The results showed that smoking history and nutritional status were independent risk factors for COPD with pulmonary infection, which agrees with results from previous studies. However, there have been no reports on whether T lymphocyte subsets in the peripheral blood can affect the risk of pulmonary infection. Therefore, we constructed ROC curves of COPD with pulmonary infection by peripheral blood T lymphocyte subset and selected the optimal cutoff. The results showed that CD4⁺/CD8⁺ cell level is an independent risk factor for COPD combined with pulmonary infection. Takabatake et al. [35] demonstrated that systemic cell-mediated immune function is impaired in COPD patients and this increases susceptibility to acute respiratory infections. It may be that the imbalance of CD4⁺/CD8⁺ cell levels in COPD patients leads to immune dysfunction and increases the patient's susceptibility to pulmonary infection. Although this study confirmed that T lymphocyte subsets play an important role in COPD with pulmonary infection, there are still some limitations of the study design. First, we did not

analyze disease etiology in these patients. Secondly, we did not conduct in-depth studies of changes in T lymphocyte subsets at the aggravation stage of COPD. These limitations need to be addressed in future research, so that further evidence can be obtained to confirm the results of this study.

In summary, COPD patients with pulmonary infection have an imbalance in T lymphocyte subsets and low immune function. In particular, CD4⁺/CD8⁺ cell imbalance was an independent risk factor for COPD patients with pulmonary infection. CD3⁺, CD4⁺ and CD4⁺/CD8⁺ cell levels were associated with the BODE index and therefore, T lymphocyte subsets may be a predictor of disease assessment and prognosis for COPD patients with pulmonary infection.

Acknowledgements

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Disclosure of conflict of interest

None.

Address correspondence to: Cunhai Zhang, Department of Intensive Care Unit, The 903rd Hospital of People's Liberation Army, No. 14, Lingyin Road, Xihu District, Hangzhou 310013, Zhejiang, China. Tel: +86-18989847027; E-mail: cunnicy@163.com

References

- [1] Lacasse Y, Cates CJ, McCarthy B and Welsh EJ. This Cochrane Review is closed: deciding what constitutes enough research and where next for pulmonary rehabilitation in COPD. *Cochrane Database Syst Rev* 2015; 18: ED000107.
- [2] Hu YH, Liang ZY, Xu LM, Xu WH, Liao H, Li R, Wang K, Xu Y, Ou CQ and Chen X. Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 3011-3019.
- [3] Yang P, Jiang SP and Lu XY. Effectiveness of continuous improvement by a clinical pharmacist-led guidance team on the prophylactic antibiotics usage rationality in intervention procedure at a Chinese tertiary teaching hospital. *Ther Clin Risk Manag* 2017; 13: 469-476.
- [4] Bhowmik A, Seemungal TA, Sapsford RJ and Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. *Thorax* 2000; 55: 114-120.
- [5] Roos AB, Sanden C, Mori M, Bjermer L, Stampfli MR and Erjefalt JS. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. *Am J Respir Crit Care Med* 2015; 191: 1232-1241.
- [6] Everaerts S, Lagrou K, Dubbeldam A, Lorent N, Vermeersch K, Van Hoeyveld E, Bossuyt X, Dupont LJ, Vanaudenaerde BM and Janssens W. Sensitization to *Aspergillus fumigatus* as a risk factor for bronchiectasis in COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2629-2638.
- [7] Zhuo S, Li N, Zheng Y, Peng X, Xu A and Ge Y. Expression of the lymphocyte chemokine XCL1 in lung tissue of COPD mice, and its relationship to CD4(+)/CD8(+) ratio and IL-2. *Cell Biochem Biophys* 2015; 73: 505-511.
- [8] Wang Y, Jiang B, Guo Y, Li W, Tian Y, Sonnenberg GF, Weiser JN, Ni X and Shen H. Cross-protective mucosal immunity mediated by memory Th17 cells against *Streptococcus pneumoniae* lung infection. *Mucosal Immunol* 2017; 10: 250-259.
- [9] Collins PF, Elia M, Kurukulaaratchy RJ and Stratton RJ. The influence of deprivation on malnutrition risk in outpatients with chronic obstructive pulmonary disease (COPD). *Clin Nutr* 2018; 37: 144-148.
- [10] Collins PF, Stratton RJ, Kurukulaaratchy RJ and Elia M. Influence of deprivation on health care use, health care costs, and mortality in COPD. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 1289-1296.
- [11] Chan KY, Li X, Chen W, Song P, Wong NWK, Poon AN, Jian W, Soyiri IN, Cousens S, Adeloje D, Sheikh A, Campbell H and Rudan I; Global Health Epidemiology Research Group (GHERG). Prevalence of chronic obstructive pulmonary disease (COPD) in China in 1990 and 2010. *J Glob Health* 2017; 7: 020704.
- [12] Karhu J, Ala-Kokko TI, Vuorinen T, Ohtonen P, Julkunen I and Syrjala HT. Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. *Cytokine* 2019; 113: 272-276.
- [13] Song Y, Chen R, Zhan Q, Chen S, Luo Z, Ou J and Wang C. The optimum timing to wean invasive ventilation for patients with AECOPD or COPD with pulmonary infection. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 535-542.
- [14] Lv Y, Lv Q, Lv Q and Lai T. Pulmonary infection control window as a switching point for sequential ventilation in the treatment of COPD

Lymphoid immune factors in COPD patients

- patients: a meta-analysis. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1255-1267.
- [15] Celli BR and MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004; 23: 932-946.
- [16] Rennard S, Thomashow B, Crapo J, Yawn B, McIvor A, Cerreta S, Walsh J and Mannino D. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD Foundation. *COPD* 2013; 10: 378-389.
- [17] Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V and Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350: 1005-1012.
- [18] Palmer K, Vetrano DL, Marengoni A, Tummolo AM, Villani ER, Acampora N, Bernabei R and Onder G. The relationship between anaemia and frailty: a systematic review and meta-analysis of observational studies. *J Nutr Health Aging* 2018; 22: 965-974.
- [19] Zhu N, Welch CL, Wang J, Allen PM, Gonzaga-Jauregui C, Ma L, King AK, Krishnan U, Rosenzweig EB, Ivy DD, Austin ED, Hamid R, Pauciulo MW, Lutz KA, Nichols WC, Reid JG, Overton JD, Baras A, Dewey FE, Shen Y and Chung WK. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. *Genome Med* 2018; 10: 56.
- [20] Garth J, Barnes JW and Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. *Int J Mol Sci* 2018; 19: 3402.
- [21] Koshak A, Koshak E and Heinrich M. Medicinal benefits of *Nigella sativa* in bronchial asthma: a literature review. *Saudi Pharm J* 2017; 25: 1130-1136.
- [22] Hodge G, Jersmann H, Tran HB, Roscioli E, Holmes M, Reynolds PN and Hodge S. Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. *Respir Res* 2015; 16: 130.
- [23] Shibata S, Miyake K, Tateishi T, Yoshikawa S, Yamanishi Y, Miyazaki Y, Inase N and Karasuyama H. Basophils trigger emphysema development in a murine model of COPD through IL-4-mediated generation of MMP-12-producing macrophages. *Proc Natl Acad Sci U S A* 2018; 115: 13057-13062.
- [24] Yang X, Huo B, Zhong X, Su W, Liu W, Li Y, He Z and Bai J. Imbalance between subpopulations of regulatory T cells in patients with acute exacerbation of COPD. *COPD* 2017; 14: 618-625.
- [25] Freeman CM, Crudgington S, Stolberg VR, Brown JP, Sonstein J, Alexis NE, Doerschuk CM, Basta PV, Carretta EE, Couper DJ, Hastie AT, Kaner RJ, O'Neal WK, Paine R 3rd, Rennard SI, Shimbo D, Woodruff PG, Zeidler M and Curtis JL. Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). *J Transl Med* 2015; 13: 19.
- [26] Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, Polak TJ, Sonstein J, Todt JC, Ames TM, Arenberg DA, Meldrum CA, Getty C, McCloskey L and Curtis JL. Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. *J Immunol* 2010; 184: 6504-6513.
- [27] Wang KS, Wang L, Zheng S and Wu LY. Associations of smoking status and serious psychological distress with chronic obstructive pulmonary disease. *Int J High Risk Behav Addict* 2013; 2: 59-65.
- [28] Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL, McCloskey L and Curtis JL. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4⁺ & CD8⁺ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. *Respir Res* 2015; 16: 94.
- [29] Jerpseth H, Dahl V, Nortvedt P and Halvorsen K. Older patients with late-stage COPD: Their illness experiences and involvement in decision-making regarding mechanical ventilation and noninvasive ventilation. *J Clin Nurs* 2018; 27: 582-592.
- [30] sbv Ipt, Boue S, Fields B, Hoeng J, Park J, Peitsch MC, Schlage WK, Taliikka M, Challenge Best P, Binenbaum I, Bondarenko V, Bulgakov OV, Cherkasova V, Diaz-Diaz N, Fedorova L, Guryanova S, Guzova J, Igorevna Koroleva G, Kozhemyakina E, Kumar R, Lavid N, Lu Q, Menon S, Ouliel Y, Peterson SC, Prokhorov A, Sanders E, Schrier S, Schwaitzer Neta G, Shvydchenko I, Tallam A, Villa-Fombuena G, Wu J, Yudkevich I and Zelikman M. Enhancement of COPD biological networks using a web-based collaboration interface. *F1000Res* 2015; 4: 32.
- [31] Kwak HJ, Park DW, Kim JE, Park MK, Koo GW, Park TS, Moon JY, Kim TH, Sohn JW, Yoon HJ, Shin DH and Kim SH. Prevalence and risk factors of respiratory viral infections in exacerbations of chronic obstructive pulmonary disease. *Tohoku J Exp Med* 2016; 240: 131-139.
- [32] Depp TB, McGinnis KA, Kraemer K, Akgun KM, Edelman EJ, Fiellin DA, Butt AA, Crystal S, Gor-

Lymphoid immune factors in COPD patients

- don AJ, Freiberg M, Gibert CL, Rimland D, Bryant KJ and Crothers K. Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. *AIDS* 2016; 30: 455-463.
- [33] Kanazawa H, Hirata K and Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. *Chest* 2003; 123: 596-599.
- [34] Shi F, Zhang Y, Qiu C, Xiong Y, Li M, Shan A, Yang Y and Li B. Effects of inhaled corticosteroids on the expression of TNF family molecules in murine model of allergic asthma. *Exp Lung Res* 2017; 43: 301-310.
- [35] Takabatake N, Sata M, Abe S, Inoue S, Saito H, Yuki H, Shibata Y and Kubota I. Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD. *Respir Med* 2005; 99: 485-492.